hydroxyurea has been researched along with Fatigue in 7 studies
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
Excerpt | Relevance | Reference |
---|---|---|
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 9.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 5.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
" Adverse events were primarily grades 1/2 with no unexpected safety signals." | 2.84 | The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). ( Byrne, J; Garg, M; Habr, D; Hasan, Y; Hunter, D; Jones, MM; Koschmieder, S; Lyons, R; Martino, B; Mesa, R; Passamonti, F; Rinaldi, C; Vannucchi, AM; Verstovsek, S; Yacoub, A; Zachee, P; Zhen, H, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bertolini, F | 1 |
Cassisa, A | 1 |
Miggiano, MC | 1 |
Gasparin, P | 1 |
Willemze, R | 1 |
Suciu, S | 1 |
Muus, P | 1 |
Halkes, CJ | 1 |
Meloni, G | 1 |
Meert, L | 1 |
Karrasch, M | 1 |
Rapion, J | 1 |
Vignetti, M | 1 |
Amadori, S | 1 |
de Witte, T | 1 |
Marie, JP | 1 |
Stein, BL | 1 |
Moliterno, AR | 1 |
Tiu, RV | 1 |
Geyer, H | 1 |
Scherber, R | 1 |
Kosiorek, H | 1 |
Dueck, AC | 1 |
Kiladjian, JJ | 1 |
Xiao, Z | 1 |
Slot, S | 1 |
Zweegman, S | 1 |
Sackmann, F | 1 |
Fuentes, AK | 1 |
Hernández-Maraver, D | 1 |
Döhner, K | 1 |
Harrison, CN | 1 |
Radia, D | 1 |
Muxi, P | 1 |
Besses, C | 1 |
Cervantes, F | 1 |
Johansson, PL | 1 |
Andreasson, B | 1 |
Rambaldi, A | 1 |
Barbui, T | 1 |
Bonatz, K | 1 |
Reiter, A | 1 |
Boyer, F | 1 |
Etienne, G | 1 |
Ianotto, JC | 1 |
Ranta, D | 1 |
Roy, L | 1 |
Cahn, JY | 1 |
Maldonado, N | 1 |
Barosi, G | 1 |
Ferrari, ML | 1 |
Gale, RP | 1 |
Birgegard, G | 1 |
Xu, Z | 1 |
Zhang, Y | 1 |
Sun, X | 1 |
Xu, J | 1 |
Zhang, P | 1 |
te Boekhorst, PA | 1 |
Commandeur, S | 1 |
Schouten, H | 1 |
Pahl, HL | 1 |
Griesshammer, M | 1 |
Stegelmann, F | 1 |
Lehmann, T | 1 |
Senyak, Z | 1 |
Vannucchi, AM | 2 |
Passamonti, F | 2 |
Samuelsson, J | 1 |
Mesa, RA | 1 |
Mesa, R | 1 |
Yacoub, A | 1 |
Zachee, P | 1 |
Garg, M | 1 |
Lyons, R | 1 |
Koschmieder, S | 1 |
Rinaldi, C | 1 |
Byrne, J | 1 |
Hasan, Y | 1 |
Verstovsek, S | 1 |
Hunter, D | 1 |
Jones, MM | 1 |
Zhen, H | 1 |
Habr, D | 1 |
Martino, B | 1 |
Vogler, S | 1 |
Burkhard, R | 1 |
Cortes, J | 1 |
Kantarjian, H | 1 |
O'Brien, S | 1 |
Robertson, LE | 1 |
Pierce, S | 1 |
Talpaz, M | 1 |
1 review available for hydroxyurea and Fatigue
Article | Year |
---|---|
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
3 trials available for hydroxyurea and Fatigue
3 other studies available for hydroxyurea and Fatigue
Article | Year |
---|---|
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; | 2017 |
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fatigue; Female; Fever; Humans; Hydroxyurea; | 2016 |
[A 69-year-old man with deep fatigue, weight loss and eosinophilia].
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Fatigue; Follow-Up St | 2005 |